Results for "The Role of Distributors in the U.S. Specialty Pharmaceuticals Value Chain"
Chip Davis Shares HDA’s 2025 Policy Priorities in Annual Chain Drug Review Column
In his annual “Health Care Outlook” column featured in Chain Drug Review, HDA’s President and CEO Chip Davis outlines a series of key policy priorities for healthcare distributors in 2025, as well as some challenges he expects the industry to face.
HDA Statement on FDA Distributor Licensure Proposed Rule
The Healthcare Distribution Alliance (HDA) released the following statement from President and CEO Chester “Chip” Davis Jr., regarding FDA’s proposed rule, issued as required by the Drug Supply Chain Security Act (DSCSA), entitled “National Standards for Licensure of Wholesale Drug Distributors and Third-Party Logistics Providers.”
HDA Urges FDA To Adopt Alternatives to Broad DSCSA Enforcement Discretion
The Healthcare Distribution Alliance (HDA) urged the Food and Drug Administration (FDA) to avoid delaying certain requirements for manufacturers and repackagers to comply with the November 27, 2023, Drug Supply Chain Security Act (DSCSA) deadline, in public comments submitted to the agency.
HDA Statement on Expiration of the COVID-19 Public Health Emergency
The Healthcare Distribution Alliance (HDA) released a statement from President and CEO Chester “Chip” Davis, Jr., on the expiration of the federal Public Health Emergency (PHE) for COVID-19.
HDA To Convene Rx Supply Chain Professionals as Industry Closes in on Drug Supply Chain Security Act Implementation Deadline
The Healthcare Distribution Alliance (HDA) will host its annual Traceability Seminar, providing an opportunity for supply chain professionals to discuss Drug Supply Chain Security Act (DSCSA) implementation.